medigraphic.com

2014, Number 2

<< Back Next >>

Revista Cubana de Angiología y Cirugía Vascular 2014; 15 (2)

Lecithin: cholesterol acyltransferase and the carotid disease

Triana MME

Language: Spanish
References: 44
Page:
PDF size: 77.87 Kb.


ABSTRACT

Introduction: lecithin:cholesterol acyltransferase is the enzyme in charge of esterifying the free extracellular cholesterol and of helping in the conversion of high density lipoprotein sub-fractions, but its role in the carotid disease is still unknown.
Objective: to identify the role of lecithin: cholesterol acyltransferase in the carotid disease, and whether it may be considered as a biomarker of the disease.
Methods: the databases MedLine, PubMed, SciELO, Web of Science, and Cuban biomedical journals of last five years (2009-2013) were reviewed. The subject headings were lecithin: cholesterol acyltransferase, dyslipidemia, carotid atherosclerosis, carotid disease.
Information synthesis: there is evidence supporting the reverse relation of high density lipoprotein-transported cholesterol and the carotid disease and of the participation of lecithin: cholesterol acyltransferase in the metabolism of these lipoproteins. However, the evidence point out that lecithin: cholesterol acyltransferase is not necessary for vascular protection and the "anti-atherogenic" effect of the enzyme depends on the quality of the said lipoproteins and the genetic component.
Conclusions: there are not enough results that allow identifying the causative relationship between lecithin: cholesterol acyltransferase and the carotid disease, since the results are not conclusive, and this enzyme cannot be considered so far a predictive biomarker of the disease.


REFERENCES

  1. Organización Mundial de la salud (OMS). Las enfermedades no transmisibles, un problema de salud de primer orden para el siglo xxi. En: Estadísticas Sanitarias Mundiales 2012. 2012 [citado 30 Oct 2013]:1-178. Disponible en:http://www.who.int/healthinfo/ES_WHS2012_Full.pdf

  2. Krishnamurthi RV, Feigin VL, Forouzanfar MH, Mensah GA, Connor M, Bennett DA. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990-2010: Findings from the Global Burden of Disease Study 2010. Lancet Global Health. 2013;1(5):e259-e81. doi: 10.1016/S2214-109X(13)70089-5

  3. MINSAP. Dirección Nacional de Registros Médicos y Estadísticas de Salud. Anuario estadístico de salud. 2012 [citado 30 Oct 2013]. Disponible en: http://www.files.sld.cu/dne/files/2013/04/anuario_2012.pdf

  4. Brott TG, Halperin JL, Abbara S, Bacharach JM, Barr JD, Bush RL, et al. Guideline on the management of patients with extracranial carotid and vertebral artery disease: Executive summary. Circulation. 2011;124(4):489-532. doi: 10.1161/CIR.0b013e31820d8d78

  5. Buergo Zuaznábar MA, Fernández Concepción O, Pérez Mellar J, Pando Cabrera A, Lara Fernández G, Lara Rodríguez R, et al. Estenosis carotídea. En: Sánchez Ferrán T, editor. Guía práctica clínica. Enfermedad cerebrovascular. La Habana: Editorial Ciencias Médicas; 2009 [citado 30 Oct 2013]:35-7. Disponible en: http://www.bvs.sld.cu/libros/guia_enf_cerebrovascular/completo.pdf

  6. Taussky P, Hanel RA, Meyer FB. Clinical considerations in the management of asymptomatic carotid artery stenosis. Neurosurgical Focus. 2011 [cited 2013 Oct 31];31(6):1-9. Available from:http://www.thejns.org/doi/pdf/10.3171/2011.9.FOCUS11222

  7. Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ (Buddy), Culebras A. An updated definition of stroke for the 21st Century. Stroke. 2013 [cited 2013 Jul 18];44:2064-89. Available from:http://www.stroke.ahajournals.org/content/44/7/2064.abstract.html doi: 10.1161/STR.0b013e318296aeca

  8. Fernández-Britto JE, Castillo Herrera JA. Aterosclerosis [editorial]. Rev Cubana Invest Bioméd. 2005 [citado 9 Oct 2013];24(3). Disponible en: http://www.scielo.sld.cu/pdf/ibi/v24n3 /ibi01305.pdf

  9. Nakano M, Stephen J, Kramer MCA, Ladich ER, Kolodgie FD, Virmani R. Insights into the natural history of atherosclerosis progression. In: Taylor AJ, Villines TC, editors. Atherosclerosis: Clinical Perspectives Through Imaging. London: Springer-Verlag; 2013. p. 3-12. doi 10.1007/978-1-4471-4288_1

  10. Thompson RC, Allam AH, Lombardi GP, Wann LS, Sutherland ML, Sutherland JD, et al. Atherosclerosis across 4000 years of human history: the Horus study of four ancient populations. Lancet. 2013 [cited 2013 Nov 5]:1-12. Available from: http://www.press.thelancet.com/atherosclerosismummies.pdf

  11. Gupta A, Baradaran H, Schweitzer AD, Kamel H, Pandya A, Delgado D, et al. Carotid plaque MRI and stroke risk. A systematic review and meta-analysis. Stroke. 2013 [cited 2013 Oct 22];44:3071-7. Available from:http://www.stroke.ahajournals.org/content/44/11/3071.full.pdf? doi: 10.1161/?StrokeAHA.113.002551

  12. Berni A, Giuliani A, Tartaglia F, Tromba L, Sgueglia M, Blasi S, et al. Effect of vascular risk factors on increase in carotid and femoral intima-media thickness. Identification of a risk scale. Atherosclerosis. 2011;216:109-14.

  13. Rundek T, Blanton SH, Bartels S, Dong Ch, Raval A, Demmer RT, et al. Traditional risk factors are not major contributors to the variance in carotid intima-media thickness. Stroke. 2013 [cited 2013 Oct 22];44:2101-8. Available from: http://www.stroke.ahajournals.org/content/44/8/2101.abstract.html doi: 10.1161/StrokeAHA.111.000745

  14. Steinberg D. In celebration of the 100th anniversary of the lipid hypothesis of atherosclerosis. J. Lipid Res. 2013;54(11):2946-9.

  15. Reiner Z. New ESC/EAS Guidelines for the management of dyslipidaemias-any controversies behind the consensus? Eur J Cardiovasc Prev Rehabil [editorial]. 2011 [cited 2013 Oct 30];18(5):7247. Available from:http://www.cpr.sagepub.com/content/18/5 /724.full.pdf+html doi: 10.1177/1741826711418946

  16. Navab M, Reddy ST, van Lenten BJ, Alan M. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nature Reviews Cardiol. 2010 [cited 2013 Nov 8];8:222-32. Available from:http://www.nature.com/nrcardio/journal/v8/n4/pdf/nrcardio.2010.222.pdf doi: 10.1038/nrcardio.2010.222

  17. Choudhury RP, Ruparelia N. High-density lipoproteins and cardiovascular disease: the plots thicken. Heart. 2013 [cited 2014 Jan 8];99(4):222-4. Available from: http://www.heart.bmj.com/content/99 /4/222.full.pdf+html

  18. Camont L, Chapman MJ, Kontush A. Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol Med. 2011;17(10):594-603.

  19. Glomset JA. The mechanism of the plasma cholesterol esterification reaction: plasma fatty acid transferase. Biochim Biophy Acta. 1962;65:128-35.

  20. Glomset JA. The plasma lecithin: cholesterol acyl transferase reaction. J Lipid Res. 1968;91:155-67.

  21. Vergeer M, Holleboom AG, Kastelein JJP, Kuivenhoven JA. The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis? [review]. J Lipid Res. 2010 [cited 2013 Nov 8];51:2058-73. Available from:http://www.jlr.org/content/51/8/2058.full.pdf doi: 10.1194/jlr.R001610

  22. Savel J, Lafitte M, Pucheu Y, Pradeau V, Tabarin A, Couffinhal T. Very low levels of HDL cholesterol and atherosclerosis, a variable relationship a review of LCAT deficiency [review]. Vas Health Risk Management. 2012;8:35761.

  23. Huth K, Kracht J, Schoenborn W, Fuhrmann W. Tangier disease (á-lipoprotein deficiency). Dtsch med Wochenschr. 1970;95(47):2357-61.

  24. Rousset X, Vaisman B, Amar M, Sethi AA, Remaley AT. Lecithin: cholesterol acyltransferase: From biochemistry to role in cardiovascular disease [review]. Curr Opin Endocrinol Diabetes Obes. 2009 [cited 2013 Nov 8];16(2):16371. Available from:: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2910390/pdf/nihms202842.pdf

  25. Holleboom AG, Kuivenhoven JA, Vergeer M, Hovingh GK, van Miert JN, Wareham NJ (†), et al. Plasma levels of lecithin:cholesterol acyltransferase and risk of future coronary artery disease in apparently healthy men and women: a prospective casecontrol analysis nested in the EPIC-Norfolk population study. J Lip Res. 2010 [cited 2013 Nov 8];51:416-21. Available from: http://www.jlr.org/content/51/2/416.full.pdf

  26. Ng DS. The role of lecithin:cholesterol acyltransferase in the modulation of cardiometabolic risks-a clinical update and emerging insights from animal models. Biochim Biophys Acta. 2012;1821(4):654-9. doi: 10.1016/j.bbalip.2011.12.012

  27. Dullaart RP, Perton F, Kappelle PJ, de Vries R, Sluiter WJ, van Tol A. Plasma lecithin: cholesterol acyltransferase activity modifies the inverse relationship of Creactive protein with HDL cholesterol in nondiabetic men. Biochim Biophys Acta. 2010;1801(1):84-8.

  28. Calabresi L, Baldassarre D, Castelnuovo S, Conca P, Bocchi L, Candini C, et al. Functional lecithin: cholesterol acyltransferase is not required for efficient atheroprotection in humans. Circulation. 2009 [cited 2013 Nov 8];120:628-35.. Available from: http://www.circ.ahajournals.org/content/120/7/628.full.pdf

  29. Calabresi L, Franceschini G. Lecithin:cholesterol acyltransferase, high-density lipoproteins, and atheroprotection in humans. Trends Cardiovasc Med. 2010;20(2)50- 3. doi: 10.1016/j.tcm.2010.03.007

  30. Haase CL, Tybjærg-Hansen A, Qayyum AA, Schou J, Nordestgaard BG, Frikke- Schmidt R. LCAT, HDL cholesterol and ischemic cardiovascular disease: A Mendelian randomization study of HDL cholesterol in 54,500 individuals. Clin Endocrinol Metabol. 2012 [cited 2013 Nov 8];97(2):E248-56. Available from: http://www.jcem.endojournals.org/content/97/2/E248.full.pdf+html

  31. Nakhjavani M, Esteghamati A, Esfahanian F, Ghanei A, Rashidi A, Hashemi S. HbA1c negatively correlates with LCAT activity in type 2 diabetes. Diabetes Res Clin Pract. 2008;81(1):38-41.

  32. Triana Mantilla ME, Fernández Montequín JI, Zapata Vinent JA, Morejón Reinoso O. Lecitin: colesterol aciltransferasa (LCAT) en pacientes con diabetes mellitus de tipo 2 con macroangiopatía diabética de miembros inferiores. Rev Cubana Angiol Cir Vasc. 2011 [citado 9 Nov 2013];11(2). Disponible en: http://www.bvs.sld.cu/revistas/ang/vol_11_2_11/ang04211.htm

  33. Ross Naylor A. Known knowns, known unknowns and unknown unknowns: A 2010 update on carotid artery disease. The Surgeon. 2010;8(2):79-86.

  34. Buergo Zuaznábar MA, Fernández Concepción O, Pérez Mellar J, Pando Cabrera A, Lara Fernández G, Lara Rodríguez R, et al. Dislipidemia. En: Sánchez Ferrán T, editor. Guía práctica clínica. Enfermedad cerebrovascular. La Habana: Editorial Ciencias Médicas; 2009 [citado 30 Oct 2013]:32-4. Disponible en: http://www.bvs.sld.cu/libros/guia_enf_cerebrovascular/completo.pdf

  35. Efthymios D, Avgerinos ED, Liapis CD. Role of lipoproteins in carotid arterial disease. Cap 4. In: Atique Gabriel E, Atique Gabriel S, editors. Inflammatory response in cardiovascular surgery. London: Springer-Verlag; 2013 [cited 2013 Oct 14]:29-36. Available from: http:/www.link.springer.com/chapter/10.1007/978-1-4471-4429- 8_4/fulltext.html

  36. SPARCL Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:54959.

  37. Sillesen H, Amarence P, Hennerici MG. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis. A secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2008;39:3297-300.

  38. Sigala F, Kotsinas A, Savari P. Oxidized LDL in human carotid plaques is related to symptomatic carotid disease and lesion instability. J Vasc Surg. 2010;52:70413.

  39. Wallenfeldt K, Fegerberg B, Wkstrand J. Oxidized low-density lipoprotein in plasma is a prognostic marker of subclinical atherosclerosis development in clinically healthy men. J Intern Med. 2004;256:41320.

  40. Ebinger M, Sievers C, Klotsche J, Schneider HJ, Leonards CO, Pieper L, et al. Triglycerides and stroke risk prediction: lessons from a prospective cohort study in German primary care patients. Front Neur. 2010;1:1-2. doi: 10.3389/fneur.2010.00148

  41. Labreuche J, Deplanque D, Touboul PJ. Association between change in plasma triglyceride levels and risk of stroke and carotid atherosclerosis systematic review and meta-regression analysis. Atherosclerosis. 2010;212:915.

  42. Dobiásová M, Frohlich J. Understanding the mechanism of LCAT reaction may help to explain the high predictive value of LDL/HDL cholesterol ratio. Physiol Res. 1998;47(6):387-97.

  43. Amarenco P, Labreuche J, Touboul PJ. High-density lipoprotein-cholesterol and risk of stroke and carotid atherosclerosis: a systematic review. Atherosclerosis. 2008;196(2):489-96.

  44. Khera AV, Marina Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, et al. Cholesterol efflux capacity, high density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127-35.




2020     |     www.medigraphic.com